HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

United Therapeutics Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

United Therapeutics Intelligence Report

Generated from 3 signals · 4 evidence sources

Type

Company Intelligence Report

Generated

Jul 22, 2026

Confidence

Moderate Confidence · 77%

Evidence

14 items

Sources

13

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

United Therapeutics maintains an active intelligence profile across Pulmonology, Pulmonary Hypertension, Oncology, Neuroblastoma, Pulmonary Arterial Hypertension. 3 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 77% across 4 tracked sources. Highest-priority development: Opportunities for patients and the public to be involved in the work of the MHRA. Regulatory precedent. Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as United Therapeutics.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    Opportunities for patients and the public to be involved in the work of the MHRA

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — BAXFENDY (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — BAXFENDY (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Condition-Specific Meeting Reports and Other Information Related to Patients' Experience

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — BAXFENDY (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — BAXFENDY (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — TYVASO (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    [IBENTO][IBENTO]PMDA-ATC GMP Inspection Seminar 2026 applications open

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 87 with buyer quality 8 (Mid-Market). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Opportunities for patients and the public to be involved in the work of the MHRA

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Condition-Specific Meeting Reports and Other Information Related to Patients' Experience

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TYVASO (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • [IBENTO][IBENTO]PMDA-ATC GMP Inspection Seminar 2026 applications open

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: PMDA, PMDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Phase III Trial of Dinutuximab in High-Risk Neuroblastoma Shows Promise

    Oncology · Neuroblastoma

  • United Therapeutics' Ralinepag Shows Potential in Improving Exercise Capacity in PH Patients

    Pulmonology · Pulmonary Hypertension

  • FDA Accepts Supplement Application for Tyvaso (Treprostinil)

    Pulmonary Arterial Hypertension · Prostacyclin Analog

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.